(0.19%) 5 141.25 points
(0.12%) 38 488 points
(0.30%) 17 900 points
(-0.10%) $83.77
(1.20%) $1.946
(0.24%) $2 352.90
(0.50%) $27.67
(1.85%) $939.15
(-0.17%) $0.933
(-0.26%) $11.00
(-0.27%) $0.798
(1.22%) $93.00
@ $1.540
发出时间: 15 Feb 2024 @ 00:12
回报率: -12.99%
上一信号: Feb 14 - 22:30
上一信号:
回报率: -1.28 %
Live Chart Being Loaded With Signals
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases...
Stats | |
---|---|
今日成交量 | 2.48M |
平均成交量 | 4.86M |
市值 | 280.56M |
EPS | $0 ( 2024-03-14 ) |
下一个收益日期 | ( $-0.0900 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.79 |
ATR14 | $0.00600 (0.45%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-29 | Dahan Michel | Sell | 8 661 | Common Stock |
2024-02-29 | Hadas Nicole R. | Sell | 5 974 | Common Stock |
2024-02-29 | Butler John P. | Sell | 46 570 | Common Stock |
2024-02-29 | Burke Steven Keith | Sell | 7 169 | Common Stock |
2024-02-27 | Hadas Nicole R. | Sell | 7 411 | Common Stock |
INSIDER POWER |
---|
87.62 |
Last 97 transactions |
Buy: 11 050 463 | Sell: 761 907 |
音量 相关性
Akebia Therapeutics Inc 相关性 - 货币/商品
Akebia Therapeutics Inc 财务报表
Annual | 2023 |
营收: | $194.62M |
毛利润: | $118.89M (61.09 %) |
EPS: | $-0.280 |
FY | 2023 |
营收: | $194.62M |
毛利润: | $118.89M (61.09 %) |
EPS: | $-0.280 |
FY | 2022 |
营收: | $292.60M |
毛利润: | $207.81M (71.02 %) |
EPS: | $-0.580 |
FY | 2021 |
营收: | $213.58M |
毛利润: | $60.18M (28.18 %) |
EPS: | $-1.700 |
Financial Reports:
No articles found.
Akebia Therapeutics Inc
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。